pioglitazone
AssetSmall moleculeAlso BR3003(T), Dapagliflozin/Pioglitazone, Alogliptin and Pioglitazone, Pioglitazone and Azilsartan
PPAR-gamma agonist improving insulin sensitivity and regulating glucose and lipid metabolism.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- Indications
- 12
- Trials
- 266
- Developers
- 2
Indications
12Diabetes
Approvedema.europa.eu7 Oct 2026
Diabetes mellitus
Approvedema.europa.eu7 Oct 2026
Type 2 diabetes
Approvedaccessdata.fda.gov7 Oct 2026
9 more
- Targets and what it contains3
- Owner and partners2
- Trials266
- Evidence for its targets4
- Competitors12
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 26 sources